Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SZKXH
ADC Name
BYON-3521
Synonyms
BYON 3521; BYON3521
   Click to Show/Hide
Organization
Syntarga BV; Byondis BV
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Structure
Antibody Name
Undisclosed
Antigen Name
Hepatocyte growth factor receptor (MET)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05323045
Phase 1
A first-in-human dose-escalation and expansion trial with the antibody-drug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-met expressing locally advanced or metastatic solid tumours.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with previously treated progressive locally advanced or metastatic solid tumors, MET positive.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT05323045  Clinical Status Phase 1
Clinical Description A first-in-human dose-escalation and expansion trial with the antibody-drug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-met expressing locally advanced or metastatic solid tumours.
References
Ref 1 A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects with Metastatic Breast Cancer NCT05261269. Cancer Res (2023) 83 (5_Supplement): OT3-28-01.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.